- Home
- ZEO vs IMRN Comparison
ZEO vs IMRN Comparison
Compare ZEO & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZEO
- IMRN
- Stock Information
- Founded
- ZEO 2005
- IMRN 1994
- Country
- ZEO United States
- IMRN Australia
- Employees
- ZEO N/A
- IMRN N/A
- Industry
- ZEO
- IMRN Biotechnology: Pharmaceutical Preparations
- Sector
- ZEO
- IMRN Health Care
- Exchange
- ZEO NYSE
- IMRN Nasdaq
- Market Cap
- ZEO 14.6M
- IMRN 15.0M
- IPO Year
- ZEO N/A
- IMRN N/A
- Fundamental
- Price
- ZEO $1.66
- IMRN $2.23
- Analyst Decision
- ZEO
- IMRN Strong Buy
- Analyst Count
- ZEO 0
- IMRN 1
- Target Price
- ZEO N/A
- IMRN $5.00
- AVG Volume (30 Days)
- ZEO 3.1M
- IMRN 6.6K
- Earning Date
- ZEO 11-20-2024
- IMRN 10-22-2024
- Dividend Yield
- ZEO N/A
- IMRN N/A
- EPS Growth
- ZEO N/A
- IMRN N/A
- EPS
- ZEO 0.67
- IMRN N/A
- Revenue
- ZEO $95,455,763.00
- IMRN $3,271,194.00
- Revenue This Year
- ZEO N/A
- IMRN N/A
- Revenue Next Year
- ZEO N/A
- IMRN N/A
- P/E Ratio
- ZEO $2.53
- IMRN N/A
- Revenue Growth
- ZEO N/A
- IMRN 171.67
- 52 Week Low
- ZEO $1.14
- IMRN $1.48
- 52 Week High
- ZEO $12.34
- IMRN $5.96
- Technical
- Relative Strength Index (RSI)
- ZEO 43.81
- IMRN 29.63
- Support Level
- ZEO $1.55
- IMRN $2.66
- Resistance Level
- ZEO $1.96
- IMRN $2.87
- Average True Range (ATR)
- ZEO 0.34
- IMRN 0.14
- MACD
- ZEO -0.01
- IMRN -0.06
- Stochastic Oscillator
- ZEO 10.74
- IMRN 1.50
About ZEO ZEO ENERGY CORP
Zeo Energy Corp is a vertically integrated provider of residential solar energy systems, other energy efficient equipment and related services currently serving customers in Florida, Texas, Arkansas, and Missouri. Its primary business activity is selling and installing residential solar energy systems that homeowners use to supplement the amount of usable electricity required to power their homes.
About IMRN Immuron Limited
Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.